“Primary Analysis of Phase 2 Results for Cemiplimab in Patients With Metastatic Basal Cell Carcinoma Who Progressed on or Were Intolerant to Hedgehog Inhibitors”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s177. https://doi.org/10.25251/skin.7.supp.177.